Category Archives: Antibody Commercialization

05Jul/19

Development Status and Trend of Antibody Drugs for Ophthalmic Diseases in the World

July 5, 2019Antibody Application, Antibody CommercializationAntibody Development, Antibody Production, Ophthalmic Diseases, Therapeutic Antibodybio-anti

Among the drugs for ophthalmic diseases, anti-VEGF drugs are developing rapidly, and aflibercept is amplified rapidly. At the same time, the development of new targets, new drug delivery methods and bispecific antibodiesRead More…

26Feb/19

New Drugs for Multiple Myeloma! Sanofi CD38 Targeted Antibody Therapy – Isatuximab’s First Phase III Clinical Study was Successful

February 26, 2019Antibody Application, Antibody Commercialization, Antibody NewsImmunotherapy Antibody, Monoclonal antibody, Tumor Antibodybio-anti

French pharmaceutical giant Sanofi recently announced that the key phase III clinical study ICARIA-MM to evaluate isatuximab in the treatment of recurrent/refractory multiple myeloma (R/R MM) has reached the main end point. TheRead More…